AllSci News
ImmunoBrain posts early safety data for PD-L1 against Alzheimer’s
ImmunoBrain, a New York–based clinical-stage company, presented Phase Ib data for IBC-Ab002, an anti-PD-L1 monoclonal antibody in early Alzheimer’s disease, at the…
Triana’s brain-penetrant molecular glue degrader TRI-611 enters clinic set for ALK+ NSCLC
Triana Biomedicines, a privately held biotechnology company based in Lexington, Massachusetts, has dosed the first patient in a Phase I/II clinical trial…
Congruence raises USD 39.5m to advance protein misfolding correctors to clinic
Congruence Therapeutics, a Montreal-based biotechnology company developing small molecule correctors for diseases of protein misfolding, has closed a USD 39.5 million financing…
Endevica spins out Kalohexis to advance melanocortin-targeted obesity and cachexia therapies
Illinois-based Endevica Bio announced the spinout of Kalohexis, a new clinical-stage biotech focused on developing therapies targeting the melanocortin system for metabolic…
Atrogi’s GRK-biased β2 agonist enters clinic aiming to achieve muscle-sparing fat loss
Stockholm-based Atrogi AB has dosed the first subjects in clinical trial evaluating the muscle physiological effects of its oral β2-adrenergic receptor therapy…
Aspen’s sasineprocel shows motor improvements in Phase I/IIa Parkinson’s disease trial
Aspen Neuroscience, a San Diego–based clinical-stage regenerative medicine company, announced 12-month data from its Phase I/IIa ASPIRO clinical trial evaluating sasineprocel (ANPD001),…
FDA approves J&J’s Icotyde for plaque psoriasis in adults and adolescents
The US FDA has approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years…
Dalriada, Topos Bio form small molecule discovery partnership for intrinsically disordered proteins
Toronto-based Dalriada Drug Discovery and San Francisco-based Topos Bio have entered a research collaboration to advance small-molecule drug discovery against intrinsically disordered…
HCW Biologics hands Phase I development of tri-specific fusion immunotherapeutic to China’s Trimmune
HCW Biologics Inc. (NASDAQ: HCWB), a Florida-based biopharma, has closed an exclusive worldwide license for HCW11-006, a preclinical fusion immunotherapeutic, signed with…
BioVie spinoff Option Therapeutics moving towards IPO for USD 21.8m
Option Therapeutics Inc. (NYSE American: OPTN), a clinical-stage biopharmaceutical company incorporated in Delaware, filed for an initial public offering of...
R1 Therapeutics licenses Alebund’s pan-phosphate transporter inhibitor alongside Series A launch
R1 Therapeutics, a newly formed clinical-stage company, has licensed exclusive rights to develop and commercialize Alebund Pharmaceuticals’ AP306 outside Greater China under…
NRx Pharma plans NDA for NRX-100 ketamine in severe depression after Type C meeting
NRx Pharmaceuticals (Nasdaq: NRXP) has confirmed its intention to submit a New Drug Application (NDA) to the US FDA for NRX-100 (preservative-free…
Immutep’s LAG3 drug eftilagimod alfa halted in Phase III for NSCLC due to futility
Sydney-based Immutep Limited announced that the Independent Data Monitoring Committee for its TACTI-004 Phase III trial recommended discontinuation of the study evaluating…
Sana reports 14-month survival of hypoimmune islet cells without immunosuppression in Type 1 diabetic patient
Seattle-based Sana Biotechnology announced 14-month follow-up data from a first-in-human study of UP421, an allogeneic islet cell therapy engineered with the company’s…
Ultragenyx gene therapy DTX301 cuts plasma ammonia in Phase III OTC deficiency trial
Novato, California-based Ultragenyx Pharmaceutical announced Phase III results for DTX301 (avalotcagene ontaparvovec), an AAV8 gene therapy for ornithine transcarbamylase deficiency, reporting a…
The AllSci Brief
Systematic R&D and deal news. Daily.